Defective wound repair driven by persistent inflammation represents a clinically challenging problem that urgently requires effective solutions. Beyond delaying tissue regeneration, uncontrolled inflammatory activity reduces patient quality of life and imposes a growing burden on medical systems. The current first-line approach for S. aureus-infected wounds, combining systemic antibiotics with surgical tissue removal, has inherent drawbacks. Debridement itself causes secondary tissue injury and procedural discomfort, and the worsening global problem of antimicrobial resistance steadily erodes the reliability of antibiotic regimens. Given these constraints, the research community has increasingly focused on deciphering the molecular basis of wound healing and identifying new targets for anti-inflammatory intervention.
In this context, traditional Chinese medicine-derived therapies have shown considerable efficacy in wound repair, including attenuation of inflammatory cascades and reduction of oxidative burden, as evidenced by studies of various herbal extracts and bioactive compounds (
29,
30). Among them, DOP, the primary bioactive component of
Dendrobium officinale, has received increasing attention. Previous work indicates that DOP has significant anti-inflammatory activity and tissue repair capabilities (
31). Nevertheless, whether DOP exerts its effects by regulating key inflammatory signaling pathways and what the precise mechanism of action is remain unclear. To address this question, we developed a mouse model of
S. aureus-infected wounds, systematically evaluated the therapeutic efficacy of DOP, and investigated its regulatory effects on the SIRT1/HMGB1/NF-κB axis.
The experimental findings demonstrated that this animal model successfully recapitulated the pathological characteristics of clinical infected wounds. DOP treatment significantly accelerated wound closure, improved the body weight trajectory of infected mice, and improved local tissue pathology, as indicated by reduced inflammatory cell infiltration, diminished tissue necrosis, and enhanced granulation tissue formation. Notably, the protective effects of DOP were significantly attenuated after treatment with EX527, a specific inhibitor of SIRT1, indicating that SIRT1 activation is a critical mediator of the therapeutic effects of DOP.
SIRT1, an NAD
+-dependent deacetylase, occupies a central position in inflammation modulation (
10,
32,
33). Accumulating evidence has confirmed that SIRT1 directly mediates HMGB1 deacetylation, promoting its nuclear retention and thereby inhibiting its cytoplasmic translocation and subsequent inflammatory responses (
34,
35). As a key late-stage inflammatory mediator, HMGB1 function is precisely regulated by acetylation modification (
36,
37). Once specific lysine positions, including K29 within HMGB1, become hyperacetylated, the protein undergoes nuclear egress, accumulates in the cytosol, and is ultimately secreted into the extracellular space (
37,
38). Once released into the extracellular milieu, HMGB1 engages TLR receptors to trigger NF-κB activation, driving a robust surge in downstream inflammatory cytokines, including TNF-α, IL-1β, and IL-6 (
39).
At the molecular level, our Western blot analysis yielded important findings. DOP intervention significantly increased SIRT1 protein expression while reducing HMGB1 acetylation at the K29 residue. In particular, DOP treatment effectively inhibited IκBα degradation and markedly decreased NF-κB p65 phosphorylation. These results suggest that DOP may regulate HMGB1 deacetylation by activating SIRT1, ultimately suppressing excessive activation of the NF-κB signaling pathway.
To validate this mechanism, we performed reverse-validation experiments. After treatment with EX527, the promoting effect of DOP on HMGB1 deacetylation and its inhibitory effect on the NF-κB signaling pathway were significantly reduced. This finding further confirms the central role of SIRT1 in the mechanism of action of DOP.
Combined immunofluorescence staining and ELISA assays showed that DOP markedly decreased acetylated HMGB1-K29 in infected wound tissues, an effect that was reversed by EX527. Meanwhile, qRT-PCR gene expression analysis demonstrated that DOP suppressed the transcription of TNF-α, IL-1β, and IL-6.
This study is exploratory mechanistic research. A small sample size (n = 3/group) was used in accordance with the 3R principles for animal welfare and because this study served as a proof-of-concept investigation to preliminarily delineate the core mechanism. All animals completed the study and were included in the final analysis. Nevertheless, the limited sample size without a priori power calculation may restrict the generalizability of the findings. In addition, bacterial burden in wound tissue was not quantified; therefore, no conclusion regarding direct antimicrobial effects can be drawn from the current data. In future studies, we will perform rigorous sample size calculations, increase the number of animals, and construct additional infection models to further validate our findings.
Taken together, this work provides a systematic mechanistic account of how DOP accelerates infected wound healing through coordinated regulation of the SIRT1/HMGB1/NF-κB cascade. The concordance between molecular readouts, including SIRT1 induction, HMGB1-K29 deacetylation, and NF-κB attenuation, and functional outcomes, including wound closure and cytokine suppression, remained consistent across all experimental arms and supports the proposed mechanism.
5.1. Conclusions
The findings of this investigation demonstrate that DOP significantly promotes the healing of S. aureus-infected wounds, as evidenced by a substantially reduced unclosed wound surface on day 14, recovery of body weight, and alleviation of tissue-level pathological injury caused by infection. At the molecular level, DOP upregulates SIRT1 expression, promotes HMGB1 deacetylation at the K29 site, and enhances its nuclear retention, thereby inhibiting its translocation to the cytoplasm and subsequent release. This action further blocks IκBα degradation and NF-κB p65 phosphorylation, attenuating overactivation of the NF-κB signaling pathway. Concurrently, DOP significantly reduces the transcription of TNF-α, IL-1β, and IL-6. Notably, these protective effects were all reversed by the SIRT1-specific inhibitor EX527.
This study systematically elucidates the molecular pathway through which DOP promotes the healing of infected wounds by regulating the SIRT1/HMGB1/NF-κB signaling axis. These insights advance knowledge of the anti-inflammatory actions of DOP and provide a basis for developing novel DOP-based wound treatment strategies.